Skip to main content

Advertisement

Table 3 Incidence rates for VTE (definite and probable) based on 4320 women and 32,508 WY of observation (1993 – 2003). Tabulation by parameters considered as potential VTE risk factors. Descriptive tabulation of events per 10,000 WY in the exposed and non-exposed group. Incidence rate ratio (IR) and 95% confidence interval (95% CI). "Exposed" was defined as the group where the risk was assumed to be higher.

From: Comparison of incidence/risk of venous thromboembolism (VTE) among selected clinical and hereditary risk markers: A community-based cohort study

  Exposed Non-exposed Overall Exp. vs. Non-exposed
Exposed vs. non-exposed WY VTE incidence per 104 WY WY VTE incidence per 104 WY WY VTE incidence per 104 WY IR (95% CI)
Demographic data        
Age: 30+ years vs. <30 12,346 17.0 20,162 6.5 32,508 10.5 2.6 (1.3–5.7)
BMI: 25+ vs. <25 8,764 17.1 23,696 8.0 32,460 10.5 2.1 (1.01–4.4)
OC use: ever vs never 30,388 10.5 2,116 9.5 32,504 10.5 1.1 (0.3–9.6)
Other hormones: ever vs. never 2,484 12.1 29,896 10.4 32,380 10.5 1.2 (0.2–3.7)
Smoking: yes, ever 16,878 10.7 15,615 10.2 32,493 10.5 1.04 (0.5–2.2)
Medical history        
Personal history of VTE: yes 318 125.8 32,190 9.3 32,508 10.5 13.5 (3.5–38.3)
Family history of VTE: yes 3,810 26.3 28,698 8.4 32,508 10,5 3.1 (1.3–6.8)
Family history of varicous veins: yes 14,764 15.6 17,744 6,2 32,508 10.5 2.5 (1.2–5.7)
Family history of MI: yes 3,919 20.4 28,589 9,1 32,508 10.5 2.2 (0.9–5.1)
Family history of stroke: yes 2,480 20.2 30,028 9,6 32,508 10.5 2.1 (0.6–5.5)
Laboratory & genetic markers        
FVL mutation§: yes 2,105 19.0 30,308 9.6 32,413 10.2 2.0 (0.5–5.7)
Prothrombin mutation§: yes 1,010 19.8 30,817 9.4 31,827 9.7 2.1 (0.24–8.3)
Protein C deficiency#: yes 1510 26.5 30,958 9.7 32,468 10.5 2.7 (0.7–7.8)
AT deficiency#: yes 1648 6.1 30,828 10.7 32,476 10.5 0.6 (0.01–3.4)
MTHFR§: yes 18,423 9.2 13,404 10.4 31,827 9.7 0.9 (0.4–1.9)
  1. § homo- and heterozygote together
  2. # definition see methods